Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites [0.03%]
纳武利尤单抗联合化疗治疗大量腹水晚期胃癌患者的疗效和安全性
Toshihiko Matsumoto,Soma Sugimoto,Reo Omori et al.
Toshihiko Matsumoto et al.
Background: Chemotherapy with an immune checkpoint inhibitor is one of the standard regimens for treating advanced gastric cancer (AGC). Ascites and peritoneal dissemination are common complications and poor prognostic fa...
Correction to "Prognostic value of preoperative fibrinogen, neutrophil-to-lymphocyte ratio, serum alpha-fetoprotein, and prealbumin for patients with primary liver cancer undergoing transarterial chemoembolization" [0.03%]
对“术前纤维蛋白原、中性粒细胞与淋巴细胞比率、血清甲胎蛋白和前白蛋白评估经导管动脉化疗栓塞治疗原发性肝癌患者预后的价值”的校正
Qi-Qi Liu,Ya-Dong Li,Jia-Xin Chen et al.
Qi-Qi Liu et al.
[This corrects the article on p. 103198 in vol. 17, PMID: 40547171.]. Keywords: Correction; World Journal of...
Impact of visceral obesity on postoperative complications and oncological outcomes in elderly patients with colorectal cancer [0.03%]
腹腔肥胖对老年结直肠癌患者术后并发症及肿瘤学结局的影响
Jie Zhou,Bing-Ping Wang,Ri-Na Su et al.
Jie Zhou et al.
Background: Elderly patients with colorectal cancer (CRC) can judge the risk of postoperative complications and oncological outcomes due to visceral obesity, which can provide data reference for the early prediction of pr...
Multimodal clinical parameters-based immune status associated with the prognosis in patients with hepatocellular carcinoma [0.03%]
基于多模态临床参数的肝癌患者免疫状态与预后的关系
Yu-Zhou Zhang,Yuan-Ze Tang,Yun-Xuan He et al.
Yu-Zhou Zhang et al.
Hepatocellular carcinoma presents with three distinct immune phenotypes, including immune-desert, immune-excluded, and immune-inflamed, indicating various treatment responses and prognostic outcomes. The clinical application of multi-omics ...
Tumor microenvironment-driven microRNA dysregulation: Key interactions in colorectal cancer progression [0.03%]
肿瘤微环境驱动的microRNA失调：结直肠癌进展中的关键相互作用
Adriana G Quiroz-Reyes,Paulina Delgado-Gonzalez,Jose Francisco Islas et al.
Adriana G Quiroz-Reyes et al.
Colorectal cancer remains one of the leading causes of morbidity and mortality worldwide. Despite notable advances in early detection and therapeutic strategies, the molecular mechanisms underlying tumor survival, chemotherapy resistance, a...
Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases [0.03%]
免疫检查点抑制剂联合化疗治疗食管癌肝转移患者的有效性和安全性
En-Hui Dai,Shu-Hao Que,Huan Xu et al.
En-Hui Dai et al.
Background: The liver represents a common site of distant metastasis in patients with esophageal cancer (EC). Conventional chemotherapy (CMT) presents limited efficacy for EC, and EC patients with liver metastases typical...
Efficacy of regorafenib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis [0.03%]
雷戈菲尼治疗晚期肝细胞癌疗效的系统评价和meta分析
Zhang Cheng,Ai-Min Yue
Zhang Cheng
Background: Regorafenib is approved as a second-line treatment for advanced hepatocellular carcinoma (HCC), but its comparative efficacy remains under evaluation. ...
Right patient approach to experimental stromal cell therapies for gastrointestinal tumors [0.03%]
胃肠肿瘤实验性间质细胞治疗的患者选择标准
Francesca Vescio,Silvia Curcio,Isabella Aquila et al.
Francesca Vescio et al.
Experimental therapies targeting immune and stromal cells, such as mast cells, cancer-associated fibroblasts, dendritic cells, and tumor endothelial cells, in the treatment of gastrointestinal solid tumors pose new and complex surgical and ...
Adult liver rhabdomyosarcoma complicated with sarcomatoid carcinoma: A case report [0.03%]
成人肝脏横纹肌肉瘤合并肉瘤样癌1例报告
Jie-Qun Ma,Chen Wang,Suo-Ni Li et al.
Jie-Qun Ma et al.
Background: Rhabdomyosarcoma (RMS) is a type of malignant tumor originating from rhabdomyocytes or mesenchymal cells differentiating into rhabdomyocytes. Hepatic pleomorphic RMS is a rare malignant liver tumor. Hepatic sa...
Molecular mosaic of colorectal cancer: Why one classification system is no longer enough? [0.03%]
结直肠癌分子图谱：为何一个分类系统不再足够？
Sunita Ahlawat,Sumanta Das
Sunita Ahlawat
Colorectal cancer (CRC) is one of the most molecularly heterogeneous malignancies, with complexity that extends far beyond traditional histopathological classifications. The consensus molecular subtypes (CMS) established in 2015 brought a m...